NovoCure Stock Rises on Earnings Beat
After NovoCure (NVCR) reported its second-quarter earnings results yesterday, its stock rose 8.58% and closed at $77.08.
Why Portola Pharmaceuticals’ Stock Price Is Plummeting Today
Today, Portola Pharmaceuticals is trading at $19.32, which is a ~7.52% decline from yesterday’s close of $20.89 on December 10.
Gauging Analysts’ Views for NovoCure Stock
Of the five analysts covering NovoCure (NVCR) stock in October, two have given it a “strong buy,” and three have given it a “buy.”
NovoCure Stock Rose after Positive Results from Clinical Trial
On September 6, NovoCure (NVCR) stock rose 5.3% to reach $45.40.
NovoCure Stock: Key Factors Driving Investors’ Interest
Currently, NovoCure’s clinical programs are evaluating the use of tumor treating fields in a number of indications.
Why Most Analysts Are Bullish on NovoCure
NovoCure’s R&D expenses are expected to increase 47.06% from $9.37 million in Q2 2017 to $13.78 million in Q2 2018.
The starting lineup for the Nasdaq All-Stars features names such as MongoDB (NASDAQ: MDB), Etsy Inc. (NASDAQ: ETSY), and Netflix Inc. (NASDAQ: NFLX).